MLTX
MoonLake ImmunotherapeuticsNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.17B
P/E Ratio
—
EPS
$-3.53
Beta
1.19
52W High
$62.75
52W Low
$5.95
50-Day MA
$17.61
200-Day MA
$25.09
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is an innovative biotechnology firm dedicated to developing groundbreaking therapies for chronic inflammatory diseases, leveraging its proprietary drug delivery technology. Currently, the company is advancing its lead candidate, a novel interleukin-17 inhibitor, through various stages of clinical trials, with the potential to transform treatment paradigms and improve patient outcomes significantly. Backed by a robust research pipeline and strategic collaborations, MoonLake is strategically positioned within the immunotherapy sector, targeting significant unmet medical needs while creating potential value for investors.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-242.22M |
| Operating Margin | 0.00% |
| Return on Equity | -60.80% |
| Return on Assets | -33.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.27 |
| Price-to-Book | 3.99 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -41.53 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $72.85M |
| Float | $39.47M |
| % Insiders | 10.25% |
| % Institutions | 75.02% |
Historical Volatility
HV 10-Day
33.66%
HV 20-Day
72.51%
HV 30-Day
72.68%
HV 60-Day
60.81%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($26.71 target)
1
Strong Buy11
Buy2
Hold2
SellData last updated: 4/30/2026